Relative Quantification of ERBB2 mRNA in Invasive Duct Carcinoma of the Breast: Correlation with ERBB-2 Protein Expression and ERBB2 Gene Copy Number
References (34)
- et al.
Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu)gene status in breast carcinoma
Mod Pathol
(2000) - et al.
The biology of erbB-2/neu/HER-2 and its role in cancer
Biochim Biophys Acta
(1994) - et al.
Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization
Mod Pathol
(2000) - et al.
HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization
Mayo Clin Proc
(2002) - et al.
Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12–21.32
Genomics
(1989) - et al.
HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach
Mod Pathol
(2000) - et al.
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer
Am J Pathol
(2002) - et al.
Concomitant oncoprotein detection with fluorescence in situ hybridization (COD-FISH):a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression
J Mol Diagn
(2000) - et al.
Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo
Lancet
(1986) - et al.
Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use
Histopathology
(2000)
Evaluating HER2 amplification and overexpression in breast cancer
J Pathol
Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications
Clin Chem
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
Science
A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration
Diagn Mol Pathol
Assessment of histological grade
HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
Am J Clin Pathol
Basic science of HER-2/neu: a review
Semin Oncol
Cited by (18)
Evaluation of HER2 gene status in breast cancer samples with indeterminate fluorescence in situ hybridization by quantitative real-time PCR
2015, Journal of Molecular DiagnosticsCitation Excerpt :To maintain high specificity, sensitivity, and performance (amplification success) of the qPCR method, we finally evaluated samples as HER2 amplified if HER2-to-reference gene copy number ratios were ≥2.2 for at least two of the reference genes. Surprisingly, although qPCR techniques are often used to detect HER2 mRNA,25–27 DNA-based PCR is not widely used to determine HER2 gene status, except by the LightCycler HER2/neu DNA Quantification kit (Roche, Mannheim, Germany).24,28–31 However, this kit only uses a single reference gene (not specified) located on chromosome 17, for which copy numbers frequently change in human cancers,32 and use of a single reference gene can clearly impair the reliability of HER2 analysis and amplification performance.
Assessment of HER-2 gene overexpression in Isfahan province breast cancer patients using Real Time RT-PCR and immunohistochemistry
2013, GeneCitation Excerpt :The routine test that is commonly used for detecting HER-2 protein overexpression is IHC, while fluorescence in-situ hybridization (FISH) is a common method for evaluating HER-2 gene amplification. More recently, Real Time Reverse Transcriptase-Polymerase Chain Reaction (Real Time RT-PCR) has been used as a complementary method for determining the level of HER-2 mRNA, but the results remain challenging and conflicting (Bossard et al., 2005; Ginestier et al., 2004; Mrhalová et al., 2003; Vinatzer et al., 2005). In the present study, we analyzed expression levels of HER-2 in human breast carcinomas and also we compared the expression levels of HER-2 mRNA with IHC scores.
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies
2009, Experimental and Molecular PathologyComparative evaluation of non-informative HER-2 immunoreactions (2<sup>+</sup>) in breast carcinomas with FISH, CISH and QRT-PCR
2007, BreastCitation Excerpt :Notably, there were cases with “low-level amplification” that showed mRNA values overlapping with those of polysomic cases and it was difficult to define cut-off values. This difficulty apparently was experienced by other investigators.19,20,22,25,28 In addition, we had to overcome technical obstacles while attempting to work with paraffin-embedded samples.
Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review
2022, Breast Care